1. Perico ME, Chinol M, Nacca A, Luison E, Paganelli G, Canevari S (2001) The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule. J Nucl Med 42(11):1697–1703
2. Harrison A, Walker CA, Parker D et al (1991) The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates. Int J Rad Appl Instrum B 18(5):469–476
3. Kozak RW, Raubitschek A, Mirzadeh S, Brechbiel MW, Junghans RP, Gansow OA, Waldmann TA (1989) Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity. Cancer Res 49(10):2639–2644
4. Knox SJ, Goris ML, Trisler K et al (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2(3):457–470
5. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351(9100):417–418